2/10 · Low — a mature bottler compounding ~4% revenue / ~12% EPS; no accelerating curve, no TAM explosion
Technicals
Uptrend but stretched — $106.61, −3.5% off 52-wk high, above 50/200-DMA, RSI 76 (overbought), +14% 12-mo (SPY +21%, QQQ +30%)
Conviction
None — 0 expert voices, 0 claims in the Synthos KB; verdict rests on fundamentals + quant
Position sizing
Defensive-income satellite, ~1–3% if owned at all; wait for a pullback
Next catalyst
2026-08-04 H1'26 earnings (Street EPS €2.46)
Single biggest risk
A mature, low-growth franchise carrying ~2.85× net-debt/EBITDA while priced near the top of its range
One-line thesis. CCEP is the Coca-Cola bottler for Western Europe and the Australia/Pacific/SE-Asia region — a genuinely defensive, cash-generative, dividend-paying compounder (FY25 revenue €20.9B, 35.6% gross margin, 24% ROE) that is doing everything right operationally, but it is a slow grower (~4% revenue) trading near its 52-week high on an overbought chart, so the honest call is Watch, not chase.
◆ Synthos call — HoldCCEP is a solid business largely reflected at ~$112 — fine to keep, no reason to chase; it gets interesting again below ~$95.
Downside Risk (lower = safer)
4/10 · Moderate
Low beta (0.48) & defensive demand, but net-debt/EBITDA 2.85× and near 52-wk high with RSI 76.
Growth Quality
5/10 · Moderate
~4% forward revenue CAGR, ~12% EPS CAGR on buybacks/margin, 24% ROE — steady, not fast.
Exponential Potential
2/10 · Low
Mature bottler; ~4% top-line, decelerating, EUR-reporting, no TAM explosion. A compounder, not an exponential.
⚖ Reverse-DCF cross-checkMarket-implied growth ≈ 26%/yrTo justify today’s $107, earnings would have to compound roughly 26% a year for 10 years (9% discount rate). Analysts forecast ~8%/yr, so the market is pricing in MORE than what the Street expects.What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.
Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.
WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.
HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.
AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.
In plain English
CCEP is the company that makes and delivers Coca-Cola, Fanta, Sprite, and Monster Energy across most of Western Europe and Australia/Southeast Asia. It doesn't own the Coke brand — it's the bottler and distributor that turns the syrup into cans on the shelf. It's a steady, boring, cash-machine kind of business: people buy fizzy drinks in good times and bad, so revenue is predictable and the company pays a solid dividend (about 2.3% a year).
The catch: the stock is priced fairly to slightly full — not a screaming bargain, not wildly expensive — and it's trading close to its 12-month high after a strong run, which usually isn't the best moment to jump in. Our verdict is Watch: a fine business to own for income and stability, but wait for a cheaper entry.
Here's what our three scores mean in everyday terms:
Downside Risk 4/10 (fairly low). The business is defensive and the stock is calm (it moves less than the market), but the company carries a meaningful amount of debt and the shares aren't cheap right now.
Growth Quality 5/10 (solid but slow). A well-run, profitable business — but it grows at the pace of a mature utility, roughly 4% a year in sales.
Exponential Potential 2/10 (low). This is a mature giant selling soft drinks in developed markets. Do not expect it to double — expect it to plod along and pay you a dividend.
The one big worry: you're paying a full-ish price for a company that only grows a few percent a year and already carries close to three years of profit in debt. If growth stalls or costs rise, there's little cushion in the price.
Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.
Relative performance vs S&P 500 & its sector (XLP (sector)), set to 100 a year ago
Solid = CCEP · dashed = S&P 500 · dotted = XLP (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
Price$106.61
Market cap$47B
P/E trailing5×
P/E FY26E / FY27E24× / 22×
EV / Sales2.4×
EV / EBITDA14.9×
Gross margin35.6%
Net margin9.3%
Dividend yield2.26%
Beta0.475
52-wk range$85 – $110
RSI(14)76
50 / 200-DMA$96 / $94
12-mo return+14% (SPY +21%)
Street target$110 ($108–$114)
Analyst grades15 Buy · 11 Hold · 2 Sell
FMP ratingB
Next earnings2026-08-05
What the experts actually said 0 traceable claims on CCEP · showing the highest-conviction voices
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
1. What it is
Coca-Cola Europacific Partners PLC (NASDAQ: CCEP) is the world's largest Coca-Cola bottler by revenue. It manufactures, distributes, and sells ready-to-drink non-alcoholic beverages — sparkling soft drinks (Coca-Cola, Fanta, Sprite), water and enhanced water, isotonics, teas, coffees, juices, energy drinks (Monster, and its own Reign/Relentless), and mixers — under license from The Coca-Cola Company (KO) and partners. It serves an estimated ~600 million consumers, employs ~41,000 people, is headquartered in Uxbridge, UK, and reports in euros (EUR) while trading in USD on the Nasdaq. Fiscal year ends December 31. CEO: Damian Gammell.
Structurally this is a bottler, not a brand owner: CCEP buys concentrate from Coca-Cola, adds the capital-intensive manufacturing/logistics layer, and captures the distribution margin. That is why gross margin (~36%) is far below a brand owner like KO — the economics are volume-and-route-density driven, not brand-royalty driven.
Revenue mix (FY2025, from filings — EUR):
By geography (segment disclosure):Europe €15.40B (74%) · Australia, Pacific & SE Asia €5.50B (26%). The 2021 Coca-Cola Amatil acquisition added the Australia/Pacific/Indonesia leg (hence the "Europacific" name).
By product (FMP segmentation not provided): management reports the portfolio as sparkling (the majority), with energy, water/sports, and coffee/tea/juice the growth adjacencies. (The FMP product-segment feed is empty for CCEP; drug-of-choice here is the geographic split above plus management commentary — see §9.)
There is a customer-concentration nuance worth naming: CCEP's entire portfolio depends on its franchise relationship with The Coca-Cola Company. That is a durable, decades-old bottling agreement — but it is a single-supplier structural dependency (§11).
2. The expert thesis — why the panel is bullish (traceable)
There is no expert thesis to report. The Synthos knowledge base contains zero claims on CCEP (total_claims: 0, net_bullish_voices: 0, empty top array). None of the tracked expert voices — bullish, bearish, or neutral — has published a traceable, dated view on this name in our KB.
Per Synthos house standard, we will not fabricate conviction. This deep dive is therefore explicitly fundamentals- and quant-driven: the verdict, scores, and price cases below rest entirely on the reported financials (FMP), the live analyst-estimate consensus (labeled as estimates), and the technical/quant blocks — not on any expert panel. Where a bottler like CCEP would benefit from expert scrutiny is on the KO franchise terms, European volume elasticity, and FX; none of that is covered in our KB today, and readers should weight this note accordingly.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
Score
0–10
The read
Downside Risk(lower = safer)
4 · Low-to-Moderate
Defensive staples demand and a low beta (0.48) cushion drawdowns, and P/E ~22× is not extreme — but net-debt/EBITDA 2.85× is meaningful leverage, the current ratio is <1, and the stock sits near its 52-wk high with RSI 76.
Growth Quality
5 · Solid but slow
24% ROE and 12.5% ROCE with a durable moat, but forward revenue CAGR is only ~4% and gross margin (~36%) is structurally capped by the bottler model. Quality yes; growth no.
Exponential Potential
2 · Low
A mature developed-market bottler. Revenue growth is decelerating (FY25 +2.3% after the Amatil-driven step-ups) and there is no TAM explosion. This is a compounder/income name, not a multibagger.
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them. (EPS in EUR — the reporting currency; the share trades in USD, so FX moves the translated multiple.)
Case
Key assumptions
Fair value
Bull
Volume/price/mix holds ~mid-single-digit, buybacks continue, energy/coffee adjacencies and Indonesia lift the mix. FY27E EPS beats to ~€5.10 (vs €4.86 cons); multiple re-rates to ~24× as a low-beta compounder.
~$130 (+22%)
Base(our anchor)
Estimates roughly hit — FY27E EPS €4.86; a steady low-single-digit grower with a 2.3% yield earns a ~22× multiple.
~$112 (+5%)
Bear
European consumer softness, FX headwind (EUR translation), input-cost or sugar-tax pressure; leverage limits buyback support. FY27E EPS misses to ~€4.40; multiple de-rates to ~18×.
~$88 (−17%)
Synthos fair value = the base case, ~$112 (+5%), with the full $88–$130 span as the honest range. This anchor sits essentially in line with the Street's $110.5 consensus (there is little to disagree about on a mature bottler — the range is narrow because the business is predictable). This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). CCEP is a decent compounder with essentially no exponential character:
Forward growth: revenue CAGR FY25→FY30E ~3.9% (€20.9B → €25.3B); EPS CAGR ~11.5% (€4.09 → €7.03) — the EPS/revenue gap comes from margin expansion, buybacks (share count fell from ~460M to ~449M), and operating leverage, not from top-line acceleration.
Acceleration (the 2nd derivative) is flat-to-negative: revenue went €13.8B (FY21) → €17.3B (FY22) → €18.3B (FY23) → €20.4B (FY24) → €20.9B (FY25, +2.3%). The big jumps were the 2021 Amatil acquisition digesting through the P&L; organic growth has settled to low single digits. There is no inflection ahead — the estimates show ~4% revenue per year to 2030.
Room to run: the developed-market non-alcoholic-beverage TAM is large but saturated and slow-growing; CCEP already serves ~600M consumers across its territories. Market cap is $47B against a mature, low-growth end market — the law of large numbers is not the constraint; the category growth rate is. There is no plausible 5× here on a beverage-distribution multiple.
Reinvestment runway: capex is ~€750M–900M/yr (about 4% of revenue) — maintenance-plus, not a transformational buildout. FCF is returned via dividend + buyback rather than reinvested into a new growth curve.
Exponential Potential: Low (2/10). Own CCEP for defensive cash generation and a growing dividend, explicitly not for a growth-multibagger. This honest framing is why it lands in the income/defensive sleeve — or on the Watch list until the price is better — not in the growth or Degen tiers.
Revenue: FY25 €20.90B, +2.3% (FY24 €20.44B, +11.7% on FY23 €18.30B — the FY24 jump reflects consolidation/mix, not organic acceleration). Multi-year trend is a mature grower.
Margins: gross 35.6% TTM (structurally capped by the bottler model), EBITDA margin ~16.4%, operating ~13.4%, net 9.3% TTM. Margins are slowly improving (net income €1.94B FY25 vs €1.42B FY24) but there is no margin-explosion story — this is a thin-margin, high-turnover distributor.
Earnings: net income €1.94B FY25 (EPS €4.09) vs €1.42B FY24 (EPS €3.08). The FY24→FY25 EPS jump partly reflects a €475M one-off drag in FY24 (elevated "other expenses") washing out — normalize before extrapolating.
Cash flow: operating CF €2.95B, capex ~−€750M, FCF €2.20B FY25 (FCF yield ~5.2%). Consistently cash-generative — the core attraction. FCF comfortably covers the ~€890M dividend and ~€1.0B FY25 buyback.
Balance sheet: total debt €10.69B, cash €0.92B, net debt €9.78B; net-debt/EBITDA ~2.85× — investment-grade (rating "B" composite in FMP, debt-to-equity score weak at 1/5) and serviceable (interest coverage ~10×), but this is the single biggest quality caveat. Current ratio 0.80 (<1) and negative working capital are normal for a fast-inventory-turn beverage distributor, not a red flag on their own.
Returns on capital: ROE 24.5%, ROIC 9.5%, ROCE 12.5% — genuinely good returns on capital, flattered on the equity line by leverage.
6. Valuation — priced in or room?
CCEP is fairly-to-fully valued, not cheap and not egregious. On trailing numbers: 21.9× EPS, 2.4× EV/sales, 14.9× EV/EBITDA, ~1.9× P/B-adjusted price-to-sales, FCF yield ~5.2%, dividend yield ~2.3%. On the forward estimate path the P/E is ~24× (FY26E €4.45) → ~22× (FY27E €4.86) → ~15× (FY30E €7.03) — the multiple compresses as EPS grinds higher, but off a modest growth base, so it is not the fast de-rating you get in a high-growth name. PEG on trailing growth is ~0.57 (looks cheap) but the forward PEG is ~2.35 (looks full) — the honest read is the forward one, because trailing EPS growth was inflated by the FY24 one-off wash-out. Street targets (context): consensus $110.5, high $114, low $108 — an unusually tight band that itself signals a predictable, fully-discovered name. Our ~$112 base FV sits right on top of consensus. Not a value buy, not a bubble — a fairly-priced defensive compounder where the entry price matters more than the thesis.
7. Technicals (from the tech block)
Trend:up. $106.61 sits above the 50-DMA ($95.59) and 200-DMA ($93.74), and the 50 is above the 200 (golden-cross posture). MACD +2.50 (positive).
Location:−3.5% off the 52-week high ($110.43), +24.8% off the 52-week low ($85.43) — near the top of its range, with a shallow max drawdown from peak (−3.5%).
Momentum: RSI(14) 76.4 — overbought (>70). This is the key technical caution: the stock is extended after a strong run, which historically is a worse entry point, not a better one.
Relative strength: CCEP +14.4% 12-mo vs SPY +20.6% and QQQ +30.3% — it has lagged both the market and the Nasdaq-100 over the year, as you'd expect from a low-beta (0.48) defensive. It outperformed on a 6-month basis (+16.4% vs SPY +8.4%) as defensives rotated in.
Read: technicals say "good business, stretched entry." The uptrend is intact but RSI 76 near the 52-wk high argues for patience — a pullback toward the rising 50-DMA (~$96) would be a materially better risk/reward. No reason to chase here.
8. Moat & competitive position
CCEP's moat is franchise-and-route-density, not brand: (1) an exclusive, long-dated bottling franchise with The Coca-Cola Company across its territories — effectively a regional monopoly on the world's strongest beverage brands; (2) distribution/route density — the cost-per-case advantage of already serving millions of outlets is very hard for a new entrant to replicate; (3) scale in manufacturing and cold-chain logistics. The flip side is that this is a capital-intensive, thin-margin, low-growth moat: it protects the cash flows but does not generate the pricing power or growth of a brand owner. The competitive frame is stable — the real risks are category (sugar taxes, health-driven volume shifts, private label) rather than a direct challenger taking share.
Peer set (market cap, from FMP): Keurig Dr Pepper $45B (closest listed beverage comp), Ambev $48B, Coca-Cola FEMSA $23B and Coca-Cola Consolidated $15B (fellow bottlers), Hershey $37B, Kimberly-Clark $38B, Kenvue $38B, Sysco $41B, Kroger $36B, Target $59B. CCEP screens as a mid-large, low-beta staples name; its ~22× P/E is roughly in line with the higher-quality staples in this group, richer than the pure bottlers (KOF, COKE) that lack its developed-market mix.
9. Management, capital allocation & guidance
Capital allocation: shareholder-return-led and disciplined — FY25 returned ~€890M in dividends (payout ~49% of earnings, ~2.3% yield) plus ~€1.0B in buybacks (share count ~460M → ~449M), funded comfortably by €2.2B FCF while paying down some debt (net long-term debt issuance −€659M FY25). This is the correct posture for a mature cash generator: return cash, delever slowly, reinvest at maintenance-plus.
Deleveraging: net-debt/EBITDA has drifted down from the post-Amatil peak toward ~2.85× — watch for continued progress; further buyback capacity depends on it.
Insider activity: the FMP insider feed is empty for the sampled window — no signal either way.
Management guidance: CCEP guides to mid-single-digit revenue and higher EPS growth (buybacks + margin) over the medium term, consistent with the analyst estimate path. There is no management voice in the Synthos KB, and the FMP transcript/Q&A is not on our plan — we rely on the reported financials and consensus estimates, both labeled by source.
10. Catalysts & what to watch
Next earnings: 2026-08-04 (H1'26 / Q2; Street EPS €2.46, revenue ~€12.2B). Key lines: organic volume vs price/mix (is growth volume-led or just pricing?), and European consumer health.
FX: EUR-reported earnings translated to a USD share price — a stronger/weaker euro moves the reported multiple independent of operations.
Deleveraging + buyback cadence: continued net-debt/EBITDA progress unlocks more buyback; a stall would cap the EPS-growth algorithm.
Category risks materializing: sugar/health taxes, volume elasticity in a cost-of-living-squeezed Europe, energy-drink category momentum (Monster/own brands).
KO franchise terms: any change to bottling agreement economics with The Coca-Cola Company.
Thesis tripwires (what would change the call): organic volumes turning negative for two consecutive halves; net-debt/EBITDA rising back toward ~3.5×; a buyback pause; or a multiple re-rate above ~24× that removes the margin of safety (a sell-side, not buy-side, trigger).
11. Key risks
Full-ish price for low growth: paying ~22× for ~4% revenue growth leaves little cushion if the modest algorithm slips.
Leverage: net-debt/EBITDA ~2.85×, current ratio 0.80, and heavy goodwill/intangibles (~57% of assets, tangible book value negative) — the balance sheet is investment-grade but not fortress; a rate or earnings shock bites harder.
Franchise dependency (structural): the entire business rests on the bottling relationship with The Coca-Cola Company — a durable but single-supplier dependency.
Category/secular: sugar taxes, health-driven shift away from sparkling, private label, and European volume elasticity in a soft consumer.
FX translation: EUR earnings vs a USD-quoted share create a persistent, non-operational swing factor for US holders.
No expert coverage: with zero KB claims, there is no independent expert scrutiny of the franchise terms, FX, or European demand behind this call — a real epistemic gap, disclosed.
12. Verdict, position sizing & monitoring
Watch. CCEP is a well-run, genuinely defensive Coca-Cola bottler — 24% ROE, €2.2B FCF, a growing dividend, a durable franchise moat, and low beta. But it is a ~4%-revenue-growth, ~2.85×-levered, EUR-reporting mature compounder trading near its 52-week high on an overbought (RSI 76) chart, at a full-ish ~22× forward P/E with only ~5% upside to our base fair value. The business quality earns a look; the entry price and the absence of any growth or exponential character keep it off the buy list today. There is also no expert coverage in the Synthos KB, so this is a fundamentals/quant call with a disclosed epistemic gap.
Sizing: if owned at all, a defensive-income satellite, ~1–3% — and better initiated on a pullback toward the rising 50-DMA (~$96) than chased near highs.
Monitoring: re-underwrite on the tripwires in §10; formal re-score each earnings print. Upgrade to Buy — Tactical on a ~10–15% pullback that restores a real margin of safety, or on evidence of organic volume acceleration.
Single biggest risk: paying a full price for a low-growth, moderately-levered franchise with no cushion if the modest growth algorithm slips.
This verdict is logged as a tracked Synthos call as of 2026-07-03 at $106.61.
Provenance & disclosures
Traceability:0 KB claims, breadth 0 — there is no expert coverage of CCEP in the Synthos knowledge base. This note is explicitly fundamentals- and quant-driven; no expert conviction is claimed or implied. Fabricated conviction is structurally impossible (claim-ID reconciliation).
Data as-of: fundamentals 2025-12-31 (FY25) · estimates & prices 2026-07-02/03. Financials are reported in EUR; the share trades in USD. Forward figures are analyst consensus (FMP), labeled as estimates.
FX caveat: EPS and revenue are EUR; the price, market cap, and fair-value targets are USD. Currency translation is a genuine, non-operational swing factor.
Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").